Le Lézard
Classified in: Health, Science and technology, Business
Subject: FINANCING AGREEMENTS

Angiochem and Xinogen to Enter License Agreement



HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales.

Angiochem is currently developing ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer. The company's next clinical trial is due to start in 2018. "Angiochem is looking forward to collaborating with Xinogen," said John Huss, Executive Chairman of Angiochem. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd., also expressed his enthusiasm and confidence about collaborating with Angiochem.

About Angiochem:

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

About Beijing Shenogen Pharma Group Ltd.:

Beijing Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. The Company possesses robust intellectual property rights around novel targets for anticancer therapies. Additional information is available at http://www.shenogen.com.


These press releases may also interest you

at 16:30
PHILADELPHIA, June 20, 2018 /PRNewswire-PRWeb/ -- The CUSM School of Medicine, a private, not-for-profit medical school, was created with a mission to improve healthcare by training exceptional physicians with a special dedication to serving...

at 16:20
Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing its continued opposition to BCRX's proposed merger with Idera Pharmaceuticals, Inc. The full text of the letter...

at 16:15
Danaher Corporation announced today that it will webcast its quarterly earnings conference call for the second quarter 2018 on Thursday, July 19, 2018 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide...

at 16:13
Memorial Hermann Southeast Hospital has received prestigious international recognition as a Baby-Friendly® Designated birth facility by Baby-Friendly USA, Inc.  "This recognition is an honor and great achievement by our...

at 16:01
Rigel Pharmaceuticals, Inc. today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting in San Francisco, June 20-23,...

at 16:01
Kindred Biosciences, Inc. , a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the termination of its "at-the-market" equity offering program (the "ATM Facility") with B. Riley FBR, Inc....




News published on 3 january 2018 at 11:03 and distributed by: